Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Nivolumab, Nivolumab Injection [Opdivo], Opdivo, nivolumab, Neoadjuvant nivolumab, Nivolumab and rHuPH20, nivolumab 480mg, Nivolumab 480mg and relatlimab 160mg
Nivolumab and Ipilimumab · 3 trials · 3 indications
The number of patients that have CR or PR plus the number of patients with stable disease as a percentage of the total number of patients in the study.
The number of patients that have CR or PR plus the number of patients that have SD, as a percentage of the total number of patients in the study.
| Arm | Type | Description |
|---|---|---|
| Nivolumab and Ipilimumab | EXPERIMENTAL | Nivolumab will be administered at a fixed dose of 240 mg every 2 weeks for a maximum period of 2 years. Nivolumab will be given in combination with ipilimumab on week 1, 7, 13 and 19. Ipilimumab will be administered at the dose of 1 mg/Kg. |
| Docetaxel | OTHER | docetaxel 75 mg/m² intravenous infusion every three weeks |
| Nivolumab | EXPERIMENTAL | Nivolumab will be administered 2 weekly by intravenous infusion in a dose of 3 mg/kg |
| Name | Type | Description |
|---|---|---|
| nivolumab and ipilimumab | DRUG | - |
| Docetaxel | DRUG | docetaxel 75 mg/m² intravenous infusion every three weeks |
| nivolumab | DRUG | - |
Inclusion Criteria: * Signed informed consent form * Age ≥ 18 years * WHO-ECOG performance status 0 or 1 * Able to comply with the study protocol, in the investigator's judgment * Patients with histologically confirmed diagnosis of the recurrence of MPM. Any pleural MPM subtype is permitted for inc...
BMS-936558, also known as nivolumab and marketed as Opdivo, is an investigational oncology drug being studied for advanced or metastatic melanoma, non-squamous cell non-small cell lung cancer, localized oesogastric adenocarcinoma, follicular lymphoma, cancer, and gastric cancer. It is developed by Bristol-Myers Squibb Company (BMY) and is currently in Phase 1 clinical development.
BMS-936558 is a monoclonal antibody (target class -mab) that targets the programmed cell death protein 1 (PD-1) receptor. By binding to PD-1, it is designed to enhance the immune system's ability to fight cancer cells. This mechanism is being evaluated across multiple oncology indications.
BMS-936558 is developed by Bristol-Myers Squibb Company, a biopharmaceutical company traded on the New York Stock Exchange under the ticker BMY. The drug is also known as nivolumab and is marketed under the brand name Opdivo.
BMS-936558 is currently in Phase 1 clinical development. It has received FDA breakthrough therapy designation and priority review status. The drug is investigational and not yet approved, with ongoing clinical trials evaluating its safety and efficacy in various cancer types.
BMS-936558 has been studied in multiple clinical trials, including NCT02741570, a Phase 3 trial in head and neck cancer, and NCT02823574, a Phase 2 trial in the same condition. Other trials include NCT03355560 and NCT03894891, both Phase 2 studies in head and neck cancer. Across 14 trials, total enrollment is 6,828 patients.
Yes, BMS-936558 is the same as Opdivo. The drug is also known as nivolumab, nivolumab injection, and nivolumab 10 mg/ml. It is being developed by Bristol-Myers Squibb and is currently in Phase 1 trials for multiple oncology indications.